Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a premium GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), today announced they have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds.
Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidates. With syntheses of these compounds first realized by Enamine, the company holds specialist knowledge that can be critical to successful scale-up. In the announced collaboration Enamine will optimize synthesis processes while TBD Biodiscovery will use the developed protocols to manufacture requested products to GMP standard.
Dr. Vladimir Ivanov, Chief of Sales and Marketing at Enamine, commented: “We recognize that the building blocks we synthesize are being incorporated into the development of new drugs. We are confident that by working in partnership with TBD Biodiscovery with their extensive experience in providing synthesis services under GMP, we can further extend the support we provide and help streamline the manufacturing process.”
Dr. Andrus Tasa, Chairman of the Management Board of TBD Biodiscovery, adds: “I have been very impressed by the creativity of Enamine’s chemists in designing new chemical synthesis. We are happy to have Enamine’s support in optimizing the chemical processes used by us for GMP manufacture.”
Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidates. With syntheses of these compounds first realized by Enamine, the company holds specialist knowledge that can be critical to successful scale-up. In the announced collaboration Enamine will optimize synthesis processes while TBD Biodiscovery will use the developed protocols to manufacture requested products to GMP standard.
Dr. Vladimir Ivanov, Chief of Sales and Marketing at Enamine, commented: “We recognize that the building blocks we synthesize are being incorporated into the development of new drugs. We are confident that by working in partnership with TBD Biodiscovery with their extensive experience in providing synthesis services under GMP, we can further extend the support we provide and help streamline the manufacturing process.”
Dr. Andrus Tasa, Chairman of the Management Board of TBD Biodiscovery, adds: “I have been very impressed by the creativity of Enamine’s chemists in designing new chemical synthesis. We are happy to have Enamine’s support in optimizing the chemical processes used by us for GMP manufacture.”
